DiaMedica Therapeutics reschedules fetal growth restriction webinar
DMAC•DiaMedica Therapeutics rescheduled its webinar to November 24, 2026, where it plans to present interim safety and clinical findings from the first six participants in two Phase 2 cohorts.
1. Webinar date changed
The virtual webinar will begin at 8 a.m. EST and cover DM199 as a potential treatment for fetal growth restriction. Presentations will include interim safety and clinical findings from the first six participants across two Phase 2 early-onset fetal growth restriction cohorts.
